Alfacalcidol

Section	Indications
Medicines for endocrine disorders ◦ Oral > Liquid: 2 µg per mL ◦ Oral > Solid > capsule: 0.25 µg; 1 µg	Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport

Beinaglutide

Section	Indications
Hypoglycaemic agents	Therapeutic equivalent to semaglutide for Obesity

Bromocriptine

Section	Indications
Medicines for disorders of the pituitary hormone system	Therapeutic equivalent to cabergoline for Other specified benign neoplasm of endocrine glands

Cabergoline

Section	Indications
Medicines for disorders of the pituitary hormone system ◦ Oral > Solid > tablet: 0.5 mg; 1 mg	Other specified benign neoplasm of endocrine glands

Calcitriol

Section	Indications
Medicines for endocrine disorders ◦ Oral > Solid > capsule: 0.25 µg; 0.5 µg	Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport

Canagliflozin

Section	Indications
Hypoglycaemic agents	Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus

Carbimazole

Section	Indications
Thyroid hormones and antithyroid medicines	Therapeutic equivalent to methimazole for Thyrotoxicosis

Dapagliflozin

Section	Indications
Hypoglycaemic agents	Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus

Diazoxide

Section	Indications
Medicines for hypoglycaemia ◦ Oral > Liquid: 50 mg per mL ◦ Oral > Solid: 50 mg	Persistent hyperinsulinaemic hypoglycaemia of infancy

Dulaglutide

Section	Indications
Hypoglycaemic agents	Therapeutic equivalent to semaglutide for Obesity Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus

Empagliflozin

Section	Indications
Hypoglycaemic agents ◦ Oral > Solid: 10 mg; 25 mg	Type 2 diabetes mellitus

Estradiol

Section	Indications
Estrogens ◦ Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg	Hypopituitarism Gonadotropin deficiency Turner syndrome

Exenatide

Section	Indications
Hypoglycaemic agents	Therapeutic equivalent to semaglutide for Obesity

Fludrocortisone

Section	Indications
Adrenal hormones and synthetic substitutes ◦ Oral > Liquid: 100 µg per mL ◦ Oral > Solid > tablet: 100 µg (acetate)	Adrenocortical insufficiency

Glibenclamide

Section	Indications
Hypoglycaemic agents ◦ Oral > Solid: 5 mg; 2.5 mg	Type 2 diabetes mellitus

Gliclazide

Section	Indications
Hypoglycaemic agents ◦ Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release	Type 2 diabetes mellitus

Glucagon

Section	Indications
Medicines for hypoglycaemia ◦ Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent	Hypoglycaemia in the context of diabetes

Hydrocortisone

Section	Indications
Adrenal hormones and synthetic substitutes ◦ Oral > Solid > tablet: 5 mg; 10 mg; 20 mg ◦ Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule	Adrenocortical insufficiency

Insulin (analogue, long-acting)

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin (analogue, rapid-acting)

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen	Type 1 diabetes mellitus Type 2 diabetes mellitus

Insulin (human, intermediate-acting)

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin (human, short-acting)

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin analogues

Section	Indications
Insulins ◦ Not specified	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin aspart

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen ◦ Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen	Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus

Insulin degludec

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 units per mL	Therapeutic equivalent to insulin glargine for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus

Insulin detemir

Section	Indications
Insulins	Therapeutic equivalent to insulin glargine for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus

Insulin glargine

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 units per mL	Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus

Insulin glulisine

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen	Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus

Insulin lispro

Section	Indications
Insulins - Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen	Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus

Iodine + potassium iodide (Lugol's solution)

Section	Indications
Thyroid hormones and antithyroid medicines - Oral > Liquid: 5% w/v + 10% w/v (aqueous)	Thyrotoxicosis

Ketoconazole

Section	Indications
Medicines for endocrine disorders - Oral > Solid > tablet: 200 mg	Cushing syndrome

Levothyroxine

Section	Indications
Thyroid hormones and antithyroid medicines - Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)	Hypothyroidism

Liraglutide

Section	Indications
Medicines for endocrine disorders - Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen	Obesity
Hypoglycaemic agents	Therapeutic equivalent to semaglutide for Obesity Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus

Medroxyprogesterone acetate

Section	Indications
Progestogens - Oral > Solid: 5 mg	Excessive menstruation with irregular cycle

Metformin

Section	Indications
Hypoglycaemic agents ◦ Oral > Solid: 500 mg (hydrochloride)	Type 2 diabetes mellitus

Methimazole

Section	Indications
Thyroid hormones and antithyroid medicines ◦ Oral > Solid > tablet: 5 mg; 10 mg	Thyrotoxicosis

Norethisterone

Section	Indications
Progestogens ◦ Oral > Solid: 5 mg	Excessive menstruation with irregular cycle Therapeutic equivalent to medroxyprogesterone acetate for Excessive menstruation with irregular cycle

Octreotide

Section	Indications
Medicines for disorders of the pituitary hormone system ◦ Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent ◦ Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)	Acromegaly or pituitary gigantism

Phosphorus

Section	Indications
Medicines for endocrine disorders ◦ Oral > Other: 500 mg in sachet (elemental phosphorus) granules ◦ Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)	Hypophosphataemic rickets

Potassium iodide

Section	Indications
Thyroid hormones and antithyroid medicines ◦ Oral > Solid > tablet: 65 mg (scored)	Thyrotoxicosis

Prednisolone

Section	Indications
Adrenal hormones and synthetic substitutes - Oral > Solid > tablet: 1 mg	Adrenocortical insufficiency

Prednisone

Section	Indications
Adrenal hormones and synthetic substitutes - Oral > Solid > tablet: 1 mg	Therapeutic equivalent to prednisolone for Adrenocortical insufficiency

Propylthiouracil

Section	Indications
Thyroid hormones and antithyroid medicines - Oral > Solid: 50 mg	Thyrotoxicosis

Semaglutide

Section	Indications
Hypoglycaemic agents - Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution - Oral > Solid > tablet: 3 mg - Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL	Obesity Type 2 diabetes mellitus

Simvastatin

Section	Indications
Medicines for endocrine disorders - Oral > Solid: 20 mg	Polycystic ovary syndrome

Somatropin

Section	Indications
Medicines for endocrine disorders - Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge	Hypoglycaemia without associated diabetes

Testosterone

Section	Indications
Androgens - Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)	Testicular dysfunction or testosterone-related disorders

Tirzepatide

Section	Indications
Hypoglycaemic agents	Therapeutic equivalent to semaglutide for Obesity Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus

Tolbutamide

Section	Indications
Hypoglycaemic agents ◦ Oral > Solid: 500 mg	Type 2 diabetes mellitus

Zoledronic acid

Section	Indications
Medicines for endocrine disorders ◦ Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	Osteogenesis imperfecta